Furthermore, CTLA‐4 is expressed by regulatory T cells (Tregs), and therapeutic anti‐CTLA‐4 antibodies may also enhance anti‐tumour immunity by depleting Tregs and neutralizing their immunosuppressive functions. This evidence concerns the gene CTLA4 and neoplasm.